Articles liés à The Mass Tort Evidence Portfolio
Synopsis
A claim inventory is not yet evidence.
A mass tort portfolio can hold thousands of claimants and millions of pages of records. An intake statement repeated in a questionnaire, a fact sheet, and three later histories is still one statement. A pharmacy printout can stop months before the injury. An automated filter can merge two separate admissions into one. Strong claims sit unnoticed in weak cohorts while weak claims absorb time and money, and the defects surface at the worst moment: a deposition, a Daubert challenge, a bellwether pool, or a settlement audit.
The Mass Tort Evidence Portfolio shows plaintiff and defense teams how to turn a claim inventory into tested, claimant-level evidence. Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, draws on more than four decades in healthcare to apply the seven pillars of the Lexcura Clinical Intelligence Model to mass tort work: Record Integrity, Baseline Profiling, Imaging Analysis, Timeline Reconstruction, Standard of Care Review, Regulatory and Compliance Overlay, and Causation Mapping. Every finding is stated as Established, Supported but disputed, Inferential, or Unresolved, and every file receives a clear decision label, so counsel knows what to advance, what to develop, and what to stop.
Inside, readers will find:
- How MDLs test claimant evidence: 28 U.S.C. 1407, new Rule 16.1, fact sheets, census orders, and Lone Pine orders
- Exposure proof from dispensing records, implant logs, and industrial hygiene data
- Baseline, imaging, and timeline analysis that separates pre-existing risk from new injury
- What FDA adverse-event data, recalls, and labeling can and cannot prove
- General and specific causation and expert reliability under Rule 702 as amended in 2023
- Tiered intake, cohorts, outliers, bellwether selection, and settlement readiness
- Quality assurance and responsible use of technology and AI
- Four complete worked files: a drug claim with weak exposure proof, a hip implant with conflicting imaging, a toxic exposure with competing causes, and a strong claim hidden in a weak cohort
- Review protocols, checklists, a glossary, and a table of authorities
Written for mass tort counsel, MDL teams, legal nurse consultants, clinical reviewers, claims administrators, and experts, this book replaces page-volume thinking with a visible, reproducible method that keeps uncertainty in view and gives counsel evidence that can withstand scrutiny.
Part of the Clinical Intelligence series by Michelle Carroll.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Résultats de recherche pour The Mass Tort Evidence Portfolio
Image d'archives
The Mass Tort Evidence Portfolio
Vendeur : California Books, Miami, FL, Etats-Unis
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. N° de réf. du vendeur I-9798952094741
Acheter neuf
EUR 54,41
Expédition à EUR 2,69
Expédition nationale : Etats-Unis
Expédition nationale : Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image d'archives
The Mass Tort Evidence Portfolio (Paperback)
impression à la demandeVendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Évaluation du vendeur 5 sur 5 étoiles
Paperback. Etat : new. Paperback. A claim inventory is not yet evidence.A mass tort portfolio can hold thousands of claimants and millions of pages of records. An intake statement repeated in a questionnaire, a fact sheet, and three later histories is still one statement. A pharmacy printout can stop months before the injury. An automated filter can merge two separate admissions into one. Strong claims sit unnoticed in weak cohorts while weak claims absorb time and money, and the defects surface at the worst moment: a deposition, a Daubert challenge, a bellwether pool, or a settlement audit.The Mass Tort Evidence Portfolio shows plaintiff and defense teams how to turn a claim inventory into tested, claimant-level evidence. Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, draws on more than four decades in healthcare to apply the seven pillars of the Lexcura Clinical Intelligence Model to mass tort work: Record Integrity, Baseline Profiling, Imaging Analysis, Timeline Reconstruction, Standard of Care Review, Regulatory and Compliance Overlay, and Causation Mapping. Every finding is stated as Established, Supported but disputed, Inferential, or Unresolved, and every file receives a clear decision label, so counsel knows what to advance, what to develop, and what to stop.Inside, readers will find: How MDLs test claimant evidence: 28 U.S.C. 1407, new Rule 16.1, fact sheets, census orders, and Lone Pine ordersExposure proof from dispensing records, implant logs, and industrial hygiene dataBaseline, imaging, and timeline analysis that separates pre-existing risk from new injuryWhat FDA adverse-event data, recalls, and labeling can and cannot proveGeneral and specific causation and expert reliability under Rule 702 as amended in 2023Tiered intake, cohorts, outliers, bellwether selection, and settlement readinessQuality assurance and responsible use of technology and AIFour complete worked files: a drug claim with weak exposure proof, a hip implant with conflicting imaging, a toxic exposure with competing causes, and a strong claim hidden in a weak cohortReview protocols, checklists, a glossary, and a table of authoritiesWritten for mass tort counsel, MDL teams, legal nurse consultants, clinical reviewers, claims administrators, and experts, this book replaces page-volume thinking with a visible, reproducible method that keeps uncertainty in view and gives counsel evidence that can withstand scrutiny.Part of the Clinical Intelligence series by Michelle Carroll. Stop drowning in endless paperwork and start building bulletproof cases. This guide teaches legal teams how to transform massive claim inventories into rigorous, trial-ready evidence that survives the toughest scrutiny. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9798952094741
Acheter neuf
EUR 57,17
Livraison gratuite
Expédition nationale : Etats-Unis
Expédition nationale : Etats-Unis
Quantité disponible : 1 disponible(s)
Image d'archives
The Mass Tort Evidence Portfolio
impression à la demandeVendeur : PBShop.store US, Wood Dale, IL, Etats-Unis
Évaluation du vendeur 5 sur 5 étoiles
PAP. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L0-9798952094741
Acheter neuf
EUR 58,89
Livraison gratuite
Expédition nationale : Etats-Unis
Expédition nationale : Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image d'archives
The Mass Tort Evidence Portfolio
impression à la demandeVendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
PAP. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L0-9798952094741
Acheter neuf
EUR 53,88
Expédition à EUR 7,02
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : Plus de 20 disponibles
Image d'archives
The Mass Tort Evidence Portfolio (Paperback)
impression à la demandeVendeur : CitiRetail, Stevenage, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Paperback. Etat : new. Paperback. A claim inventory is not yet evidence.A mass tort portfolio can hold thousands of claimants and millions of pages of records. An intake statement repeated in a questionnaire, a fact sheet, and three later histories is still one statement. A pharmacy printout can stop months before the injury. An automated filter can merge two separate admissions into one. Strong claims sit unnoticed in weak cohorts while weak claims absorb time and money, and the defects surface at the worst moment: a deposition, a Daubert challenge, a bellwether pool, or a settlement audit.The Mass Tort Evidence Portfolio shows plaintiff and defense teams how to turn a claim inventory into tested, claimant-level evidence. Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, draws on more than four decades in healthcare to apply the seven pillars of the Lexcura Clinical Intelligence Model to mass tort work: Record Integrity, Baseline Profiling, Imaging Analysis, Timeline Reconstruction, Standard of Care Review, Regulatory and Compliance Overlay, and Causation Mapping. Every finding is stated as Established, Supported but disputed, Inferential, or Unresolved, and every file receives a clear decision label, so counsel knows what to advance, what to develop, and what to stop.Inside, readers will find: How MDLs test claimant evidence: 28 U.S.C. 1407, new Rule 16.1, fact sheets, census orders, and Lone Pine ordersExposure proof from dispensing records, implant logs, and industrial hygiene dataBaseline, imaging, and timeline analysis that separates pre-existing risk from new injuryWhat FDA adverse-event data, recalls, and labeling can and cannot proveGeneral and specific causation and expert reliability under Rule 702 as amended in 2023Tiered intake, cohorts, outliers, bellwether selection, and settlement readinessQuality assurance and responsible use of technology and AIFour complete worked files: a drug claim with weak exposure proof, a hip implant with conflicting imaging, a toxic exposure with competing causes, and a strong claim hidden in a weak cohortReview protocols, checklists, a glossary, and a table of authoritiesWritten for mass tort counsel, MDL teams, legal nurse consultants, clinical reviewers, claims administrators, and experts, this book replaces page-volume thinking with a visible, reproducible method that keeps uncertainty in view and gives counsel evidence that can withstand scrutiny.Part of the Clinical Intelligence series by Michelle Carroll. Stop drowning in endless paperwork and start building bulletproof cases. This guide teaches legal teams how to transform massive claim inventories into rigorous, trial-ready evidence that survives the toughest scrutiny. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9798952094741
Acheter neuf
EUR 59,08
Expédition à EUR 44,22
Expédition depuis Royaume-Uni vers Etats-Unis
Expédition depuis Royaume-Uni vers Etats-Unis
Quantité disponible : 1 disponible(s)
Image d'archives
The Mass Tort Evidence Portfolio (Paperback)
impression à la demandeVendeur : AussieBookSeller, Truganina, VIC, Australie
Évaluation du vendeur 5 sur 5 étoiles
Paperback. Etat : new. Paperback. A claim inventory is not yet evidence.A mass tort portfolio can hold thousands of claimants and millions of pages of records. An intake statement repeated in a questionnaire, a fact sheet, and three later histories is still one statement. A pharmacy printout can stop months before the injury. An automated filter can merge two separate admissions into one. Strong claims sit unnoticed in weak cohorts while weak claims absorb time and money, and the defects surface at the worst moment: a deposition, a Daubert challenge, a bellwether pool, or a settlement audit.The Mass Tort Evidence Portfolio shows plaintiff and defense teams how to turn a claim inventory into tested, claimant-level evidence. Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, draws on more than four decades in healthcare to apply the seven pillars of the Lexcura Clinical Intelligence Model to mass tort work: Record Integrity, Baseline Profiling, Imaging Analysis, Timeline Reconstruction, Standard of Care Review, Regulatory and Compliance Overlay, and Causation Mapping. Every finding is stated as Established, Supported but disputed, Inferential, or Unresolved, and every file receives a clear decision label, so counsel knows what to advance, what to develop, and what to stop.Inside, readers will find: How MDLs test claimant evidence: 28 U.S.C. 1407, new Rule 16.1, fact sheets, census orders, and Lone Pine ordersExposure proof from dispensing records, implant logs, and industrial hygiene dataBaseline, imaging, and timeline analysis that separates pre-existing risk from new injuryWhat FDA adverse-event data, recalls, and labeling can and cannot proveGeneral and specific causation and expert reliability under Rule 702 as amended in 2023Tiered intake, cohorts, outliers, bellwether selection, and settlement readinessQuality assurance and responsible use of technology and AIFour complete worked files: a drug claim with weak exposure proof, a hip implant with conflicting imaging, a toxic exposure with competing causes, and a strong claim hidden in a weak cohortReview protocols, checklists, a glossary, and a table of authoritiesWritten for mass tort counsel, MDL teams, legal nurse consultants, clinical reviewers, claims administrators, and experts, this book replaces page-volume thinking with a visible, reproducible method that keeps uncertainty in view and gives counsel evidence that can withstand scrutiny.Part of the Clinical Intelligence series by Michelle Carroll. Stop drowning in endless paperwork and start building bulletproof cases. This guide teaches legal teams how to transform massive claim inventories into rigorous, trial-ready evidence that survives the toughest scrutiny. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. N° de réf. du vendeur 9798952094741
Acheter neuf
EUR 80,18
Expédition à EUR 33,13
Expédition depuis Australie vers Etats-Unis
Expédition depuis Australie vers Etats-Unis
Quantité disponible : 1 disponible(s)
Image d'archives
The Mass Tort Evidence Portfolio
impression à la demandeVendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - A claim inventory is not yet evidence.A mass tort portfolio can hold thousands of claimants and millions of pages of records. An intake statement repeated in a questionnaire, a fact sheet, and three later histories is still one statement. A pharmacy printout can stop months before the injury. An automated filter can merge two separate admissions into one. Strong claims sit unnoticed in weak cohorts while weak claims absorb time and money, and the defects surface at the worst moment: a deposition, a Daubert challenge, a bellwether pool, or a settlement audit.The Mass Tort Evidence Portfolio shows plaintiff and defense teams how to turn a claim inventory into tested, claimant-level evidence. Michelle Carroll, Founder and Chief Clinical Strategist of Lexcura Summit, draws on more than four decades in healthcare to apply the seven pillars of the Lexcura Clinical Intelligence Model to mass tort work: Record Integrity, Baseline Profiling, Imaging Analysis, Timeline Reconstruction, Standard of Care Review, Regulatory and Compliance Overlay, and Causation Mapping. Every finding is stated as Established, Supported but disputed, Inferential, or Unresolved, and every file receives a clear decision label, so counsel knows what to advance, what to develop, and what to stop.Inside, readers will find:How MDLs test claimant evidence: 28 U.S.C. 1407, new Rule 16.1, fact sheets, census orders, and Lone Pine ordersExposure proof from dispensing records, implant logs, and industrial hygiene dataBaseline, imaging, and timeline analysis that separates pre-existing risk from new injuryWhat FDA adverse-event data, recalls, and labeling can and cannot proveGeneral and specific causation and expert reliability under Rule 702 as amended in 2023Tiered intake, cohorts, outliers, bellwether selection, and settlement readinessQuality assurance and responsible use of technology and AIFour complete worked files: a drug claim with weak exposure proof, a hip implant with conflicting imaging, a toxic exposure with competing causes, and a strong claim hidden in a weak cohortReview protocols, checklists, a glossary, and a table of authoritiesWritten for mass tort counsel, MDL teams, legal nurse consultants, clinical reviewers, claims administrators, and experts, this book replaces page-volume thinking with a visible, reproducible method that keeps uncertainty in view and gives counsel evidence that can withstand scrutiny.Part of the Clinical Intelligence series by Michelle Carroll. N° de réf. du vendeur 9798952094741
Acheter neuf
EUR 82,62
Expédition à EUR 35
Expédition depuis Allemagne vers Etats-Unis
Expédition depuis Allemagne vers Etats-Unis
Quantité disponible : 2 disponible(s)
Image fournie par le vendeur
The Mass Tort Evidence Portfolio
impression à la demandeVendeur : preigu, Osnabrück, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Taschenbuch. Etat : Neu. The Mass Tort Evidence Portfolio | Michelle Carroll | Taschenbuch | Englisch | 2026 | Lexcura Summit | EAN 9798952094741 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. N° de réf. du vendeur 138092728
Acheter neuf
EUR 114,20
Expédition à EUR 70
Expédition depuis Allemagne vers Etats-Unis
Expédition depuis Allemagne vers Etats-Unis
Quantité disponible : 5 disponible(s)